142 related articles for article (PubMed ID: 26805364)
1. [FOLFIRINOX Combination Chemotherapy in Patients with Metastatic or Recurrent Pancreatic Cancer--A Single Institution Experience].
Takeda Y; Katsura Y; Ohmura Y; Morimoto Y; Ishida T; Motoyama Y; Ohneda Y; Sato Y; Kuwahara R; Murakami K; Naito A; Kagawa Y; Okishiro M; Takeno A; Egawa C; Kato T; Tamura S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2360-3. PubMed ID: 26805364
[TBL] [Abstract][Full Text] [Related]
2. [The Treatment Outcomes of FOLFIRINOX for Unresectable and Recurrent Pancreatic Cancer].
Sakamoto T; Takeda Y; Ohmura Y; Katsura Y; Mori R; Nose Y; Kawai K; Murakami K; Naito A; Inatome J; Kagawa Y; Masuzawa T; Takeno A; Egawa C; Murata K
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1751-1753. PubMed ID: 29394764
[TBL] [Abstract][Full Text] [Related]
3. [Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
Takeda Y; Katsura Y; Ohmura Y; Sakamoto T; Akiyama Y; Kuwahara R; Morimoto Y; Ishida T; Oneda Y; Murakami K; Naito A; Kagawa Y; Takeno A; Kato T; Tamura S
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1674-1677. PubMed ID: 28133095
[TBL] [Abstract][Full Text] [Related]
4. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.
Guion-Dusserre JF; Bertaut A; Ghiringhelli F; Vincent J; Quipourt V; Marilier S; Tharin Z; Bengrine-Lefevre L
World J Gastroenterol; 2016 Nov; 22(42):9378-9386. PubMed ID: 27895425
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer.
Wang ZQ; Zhang F; Deng T; Zhang L; Feng F; Wang FH; Wang W; Wang DS; Luo HY; Xu RH; Ba Y; Li YH
Cancer Commun (Lond); 2019 May; 39(1):26. PubMed ID: 31068222
[TBL] [Abstract][Full Text] [Related]
9. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Peddi PF; Lubner S; McWilliams R; Tan BR; Picus J; Sorscher SM; Suresh R; Lockhart AC; Wang J; Menias C; Gao F; Linehan D; Wang-Gillam A
JOP; 2012 Sep; 13(5):497-501. PubMed ID: 22964956
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
[TBL] [Abstract][Full Text] [Related]
12. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
Li J; Merl M; Lee MX; Kaley K; Saif MW
Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Ozaka M; Ishii H; Sato T; Ueno M; Ikeda M; Uesugi K; Sata N; Miyashita K; Mizuno N; Tsuji K; Okusaka T; Furuse J
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1017-1023. PubMed ID: 29633005
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
[TBL] [Abstract][Full Text] [Related]
16. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.
Todaka A; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Nakamori S; Yachi Y; Henmi T; Kobayashi M; Boku N; Mori K; Fukutomi A
Pancreas; 2018; 47(5):631-636. PubMed ID: 29683973
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.
Okusaka T; Ikeda M; Fukutomi A; Ioka T; Furuse J; Ohkawa S; Isayama H; Boku N
Cancer Sci; 2014 Oct; 105(10):1321-6. PubMed ID: 25117729
[TBL] [Abstract][Full Text] [Related]
19. [Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].
Takeda Y; Nakahira S; Katsura Y; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Suzuki R; Taniguchi H; Egawa C; Kato T; Tamura S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1884-6. PubMed ID: 24393954
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
Lu M; Wang Y; Liu W; Bai C; Xu J; Shen L
Hepatogastroenterology; 2014 Jun; 61(132):1018-23. PubMed ID: 26158159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
